Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 1079-1085

  Himoto, Takashi ^a,b   Kuriyama, Shigeki ^b   Zhang, Jian Ying ^a,c   Chan, Edward K L ^a,d   Kimura, Yasuhiko ^b   Masaki, Tsutomu ^b   Uchlda, Naohito ^b   Nishioka, Mikio ^b   Tan, Eng M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

Autoantibody; C myc; Hepatocellular carcinoma; Insulin like growth factor II mRNA binding protein; P53; Survivin; Tumor associated antigen

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; BIRC5 PROTEIN, HUMAN; COMPLEMENTARY DNA; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; MYC PROTEIN; PROTEIN P53; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMANS; LIVER; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644831393     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.1079     Document Type: Article

References (55)

1. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K and Shoenfeld Y: Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60: 433-440,2001.
2. Old LJ and Chen YT: New paths in human cancer serology. J Exp Med 187: 1163-1167, 1998.
3. Tan EM: Autoantibodies in pathology and cell biology. Cell 67: 841-842, 1991.
4. Disis ML, Pupa SM, Gralow LR, Dittadi R, Menard S and Cheever MA: High titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997.
5. Crawford LV, Pirn DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
6. Covini G, Chan EKL, Nishioka M, Morshed SA, Reed SI and Tan EM: Immune response to cyclin Bl in hepatocellular carcinoma. Hepatology 25: 75-80, 1997.
7. Casiano, CA, Humbel RL, Peebles C, Covini G and Tan EM: Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun 8: 575-586, 1995.
8. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J and Delattre JY: Cell mediated autoimmunity in paraneoplastic neurological syndrome with anti-Hu antibodies. Ann Neurol 45: 162-167, 1999.
9. Drlicek M, Bianchi G, Bogliun G, et al: Antibodies of anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 244: 85-89, 1997.
10. Davidoff AM, Humphrey PA, Iglehart JD and Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006-5010, 1991.
11. Volkmann M, Muller M, Hoffmann WJ, et al: The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the a-fetoprotein status. Hepatology 18: 559-565, 1993.
12. Labrecque S, Naor N, Thomson D and Matlashewski G: Analysis of anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471, 1993.
13. Soussi T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2001.
14. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
15. Houbiers JG, van der Burg SH, van de Watering LM, et al Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 631-641, 1995.
16. Okuda K: Hepatocellular carcinoma. J Hepatol 32 (Suppl. 1): 225-237, 2000.
17. Kurokohchi K, Watanabe S, Masaki T, et al. Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency alone for patients with hepatocellular carcinoma. World J Gastroenterol 11: 1426-1432,2005.
18. Kurokohchi K, Watanabe S, Masaki T, et al Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. Int J Oncol 21: 611-615, 2002.
19. Kurokohchi K, Watanabe S, Masaki T, et al: Combined use of percutaneous ethanol injection and radiofrequency ablation for effective treatment of hepatocellular carcinoma. Int J Oncol 21: 841-846,2002.
20. Watanabe S, Kurokohchi K, Masaki T, et al Enlargement of thermal ablation zone by the combination of ethanol injection and radiofrequency ablation in excised bovine liver. Int J Oncol 24: 279-284, 2004.
21. Kurokohchi K, Masaki T, Miyauchi Y, et al Efficacy of combination therapies of percutaneous or laparoscopic ethanollipiodol injection and radiofrequency ablation. Int J Oncol 25: 1737-1743,2004.
22. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ and van Gulik TM: Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol 31: 331-347, 2005.
23. Lin SM, Lin CJ, Lin CC, Hsu CW and Chen YC: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <4 cm. Gastroenterology 127: 1714-1723,2004.
24. Imai H, Chan EKL, Kiyosawa K, Fu XD and Tan EM: Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 92: 2419-2426, 1993.
25. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM and Tan EM: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140: 859-870, 1992.
26. Muro Y, Chan EKL, Landberg G and Tan EM: A cell-cycle nuclear antoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun 207: 1029-1037, 1995.
27. Imai H, Furuta K, Landberg G, Kiyosawa K, Liu LF and Tan EM: Autoantibodies to DNA topoisomerase II in primary liver cancer. Clin Cancer Res 1: 417-424, 1995.
28. Zhang JY, Chan EKL, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motif is an autoantigen in human hepatocellular carcinoma. J Exp Med 189: 1101-1110, 1999.
29. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19: 1262-1270, 1999.
30. Ross AF, Oleynikov Y, Kilauskis EH, Taneja KL and Singer RH: Characterization of B-actin mRNA zipcode-binding protein. Mol Cell Biol 17:2158-2165, 1997.
31. Doyle GA, Bets NA, Leeds PF, Fleisig AJ, Prokipcak RD and Ross J: The c-myc coding region determinant-binding protein: a member of a family of KH domains RNA-binding proteins. Nucleic Acids Res 26: 5036-5044, 1998.
32. Miieller-Plillasch F, Lacher U, Wallrapp C, et al Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14: 2729-2733, 1997.
33. Himoto T, Kuriyama S, Zhang JY, Chan EKL, Nishioka M and Tan EM: Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol 26: 311-317, 2005.
34. Ben-Mahrez K, Thierry D, Sorokine I, Danna-Muller A and Komiyama M: Detection of circulating antibodies against c-myc protein in cancer patient sera. Br J Cancer 57: 529-534, 1988.
35. Rohayem J, Diestelkoetter P, Weigle B, et al: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60: 1815-1817, 2000.
36. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62 (Suppl. 1): 8-17, 2002.
37. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A and Tanaka E: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127 (Suppl. 1): S17-S26, 2004.
38. Chan EKL and Pollard KM: Autoantibodies to ribonucleoprotein particles by immunoblotting. In: Manual of Clinical Laboratory Immunology. Rose NR, Conway De Macario E, Fahey JL, Friedman H and Penn GM (eds). American Society for Microbiology, Washington, DC, pp755-761, 1992.
39. Bergstrand CG and Czar B: Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest 8: 174, 1956.
40. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K and Endo Y: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 328: 1802-1806, 1993.
41. Daniele B, Bencivenga A, Megna AS and Tinessa V: a-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127: S108-S112, 2004.
42. Ryder SD, Rizzi PM, Volkmann M, et al: Use of p53 protein in patients with hepatocellular carcinoma. J Clin Pathol 49: 295-299, 1996.
43. Kondo F, Wada K, Nagato Y, et al: Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9: 751-755, 1989.
44. Gebo K, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS and Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 36 (Suppl. 1): S84-S92, 2002.
45. Raedle J, Roth WK, Oremek G, Caspary WF and Zeuzem S: a-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sei 40: 2587-2594, 1995.
46. Imai H, Nakano Y, Kiyosawa K and Tan EM: Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 71: 26-35, 1993.
47. Lubin R, Zalcman G, Bouchet L, et al: Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701-702, 1995.
48. Trivers GE, De Benedetti VM, Cawley HL, et al:. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predict a diagnosis of cancer. Clin Cancer Res 2: 1767-1775, 1996.
49. Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R and Komiyama M: Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46: 35-38, 1990.
50. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanism in tumor genesis. J Clin Invest 108: 1411-1415,2001.
51. Chan EKL, Himoto T and Zhang JY: Autoantibodies in liver diseases and hepatocellular carcinoma. In: Liver Immunology. Gershwin ME, Vierling MJM and Manns MP (eds). Hanley & Belfus Inc., Philadelphia, pp151-169, 2003.
52. Zhang JY, Chan EKL, Peng XX, Lu M, Wang X, Mueller F and Tan EM: Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 100:149-156,2001.
53. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL and Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12: 136-143, 2003.
54. Qin G, Su J, Ning Y, Duan X, Luo D and Lotlikar PD: P53 protein expression in patients with hepatocellular carcinoma from the high incidence area of Guangxi, southern China. Cancer Lett 121: 203-210, 1997.
55. Bressac B, Kew M, Wands J and Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431, 1991.